SEC Form 4 · accession 0001209191-17-059634
Dimension Therapeutics, Inc. · DMTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Samuel C. Wadsworth
Officer — Chief Scientific Officer
Period of report
Nov 7, 2017
Accepted (ET)
Nov 7, 2017 · 5:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001592288
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Nov 7, 2017 | D | 278,035 | — | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $7.14 | Nov 7, 2017 | D | 50,000 | D | — | Jan 31, 2026 | Common Stock | 50,000 | 0 | D |
| Stock Option (Right to Buy)F3 | $1.90 | Nov 7, 2017 | D | 60,000 | D | — | Jan 31, 2027 | Common Stock | 60,000 | 0 | D |
Explanation of responses
- F1Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated October 2, 2017, between the Issuer, Ultragenyx Pharmaceutical Inc. ("Ultragenyx"), and Mystic River Merger Sub Inc., a direct, wholly-owned subsidiary of Ultragenyx, in exchange for a cash payment of $6.00 per share.
- F2This stock option, which vests in equal monthly installments over 48 months beginning January 27, 2016, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.
- F3This stock option, which vests in equal monthly installments over 48 months beginning January 18, 2017, was assumed by Ultragenyx and converted in accordance with the exchange ratio as set forth in the Merger Agreement.